Boston Scientific shows strong profit growth:
This article was originally published in Clinica
Executive Summary
Boston Scientific has wiped out its first-half loss with net income of $47 million in the third quarter, up 29% on the previous year. In the first nine months net income was $24.3 million compared with $52.6 million a year earlier. Boston's third-quarter sales were 29% higher at $232.8 million and 28% up at $675.8 million in the first nine months. CEO Pete Nicholas says Boston had "excellent results in both vascular and non-vascular businesses". The three acquisitions this autumn - EP Technologies, Meadox Medicals and Heart Technology - will "further improve Boston's strategic position" in less invasive medicine, Mr Nicholas adds.
You may also be interested in...
Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
Hair Supplement Linked To Cases Of Severe Hepatitis In France
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: